CoChat

Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic

Open access
Altomare, Daniele, Stampacchia, Sara, Ribaldi, Federica, Tomczyk, Szymon, Chevalier, Claire, Poulain, Géraldine, Asadi, Saina, Bancila, Bianca, Marizzoni, Moira, Martins, Marta, Lathuiliere, Aurelien, Scheffler, Max, Ashton, Nicholas J, Zetterberg, Henrik, Blennow, Kaj, Kern, Ilse, Frias, Miguel, Garibotto, Valentina, Frisoni, Giovanni B · 2023 · Journal of Neurology, Neurosurgery & Psychiatry
Cited by 62

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: The key Alzheimer’s disease (AD) biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-positron emission tomography (PET) and tau-PET), invasive (cerebrospinal fluid Aβ 42 and p-tau 181), or poorly specific (atrophy on MRI and hypometabolism on fluorodeoxyglucose-PET). Recently developed plasma biomarkers could significantly enhance the efficiency of the diagnostic pathway in memory clinics and improve patient care. This study aimed to: (1) confirm the correlations between plasma and traditional AD biomarkers, (2) assess the diagnostic accuracy of plasma biomarkers as compared with traditional biomarkers, and (3) estimate the proportion of traditional exams potentially saved thanks to the use of plasma biomarkers. Methods: Participants were 200 patients with plasma biomarkers and at least one traditional biomarker collected within 12 months. Results: Overall, plasma biomarkers significantly correlated with biomarkers assessed through traditional techniques: up to r=0.50 (p<0.001) among amyloid,r=0.43 (p=0.002) among tau, and r=−0.23 (p=0.001) among neurodegeneration biomarkers. Moreover, plasma biomarkers showed high accuracy in discriminating the biomarker status (normal or abnormal) determined by using traditional biomarkers: up to area under the curve (AUC)=0.87 for amyloid, AUC=0.82 for tau, and AUC=0.63 for neurodegeneration status. The use of plasma as a gateway to traditional biomarkers using cohort-specific thresholds (with 95% sensitivity and 95% specificity) could save up to 49% of amyloid, 38% of tau, and 16% of neurodegeneration biomarkers. Conclusion: The implementation of plasma biomarkers could save a remarkable proportion of more expensive traditional exams, making the diagnostic workup more cost-effective and improving patient care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2022-330619

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 62

Metadata

Authors
Altomare, D., Stampacchia, S., Ribaldi, F., Tomczyk, S., Chevalier, C., Poulain, G., Asadi, S., Bancila, B., Marizzoni, M., Martins, M., Lathuiliere, A., Scheffler, M., Ashton, N. J., Zetterberg, H., Blennow, K., Kern, I., Frias, M., Garibotto, V., & Frisoni, G. B.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2023-04-03
Volume
94
Issue
6
Pages
420-427
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W4362522071
Cited by
62
References
15
FWCI
11.09
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic. https://app.cochat.ai/papers/10.1136/jnnp-2022-330619
The paper
Altomare, D., Stampacchia, S., Ribaldi, F., Tomczyk, S., Chevalier, C., Poulain, G., Asadi, S., Bancila, B., Marizzoni, M., Martins, M., Lathuiliere, A., Scheffler, M., Ashton, N. J., Zetterberg, H., Blennow, K., Kern, I., Frias, M., Garibotto, V., & Frisoni, G. B. (2023). Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2022-330619

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.